nature portfolio

Corresponding author(s):	Yingxia Wen
Last updated by author(s):	Yingxia Wen

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study.

For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
x The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
🔲 🗽 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and code
Policy information about <u>availability of computer code</u>
Data collection N/A
Data analysis
N/A For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio <u>guidelines for submitting code & software</u> for further information.
Data
Data
Policy information about <u>availability of data</u> All manuscripts must include a <u>data availability statement</u> . This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement adheres to our policy
Provided

Research invo	olving hur	man participants, their data, or biological material
Policy information ab and sexual orientatio		ith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> hnicity and racism.
Reporting on sex ar	nd gender	n/a
Reporting on race, other socially releva		n/a
Population characte	eristics	n/a
Recruitment		n/a
Ethics oversight		n/a
Note that full information	on on the appro	val of the study protocol must also be provided in the manuscript.
Field-spec	cific re	porting
Please select the one	below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
x Life sciences	Ве	havioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the	document with a	ll sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scienc	ces stu	dy design
All studies must disclo	ose on these p	points even when the disclosure is negative.
Sample size	n/a precl	inical
Data exclusions	n/a prec	linical
Replication	n/a prec	linical
Randomization	n/a pre	clinical
Blinding	n/a	
Behaviour	ral & so	ocial sciences study design
All studies must disclo	ose on these p	points even when the disclosure is negative.
Study description		
Research sample		
Sampling strategy		

Study description	
Research sample	
Sampling strategy	
Data collection	
Timing	
Data exclusions	
Non-participation	
Randomization	

l studies must disclose or	n these points even when the disclosure is negative.
Study description	
Research sample	
Sampling strategy	
Data collection	
Timing and spatial scale	
Data exclusions	
Reproducibility	
Randomization	
Blinding	
Field conditions	n/a
Access & import/export	
Disturbance	
e require information from a	or specific materials, systems and methods authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material evant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Naterials & experime	
/a Involved in the study Antibodies Eukaryotic cell lines	ChIP-seq x Flow cytometry
Palaeontology and a	With based fredrontinging
x Animals and other o	
	organisms

Antibodies

T II T C I D C G I C C	
Antibodies used	n/a
Validation	n/a

Eukaryotic cell lin	es
Policy information about <u>ce</u>	Il lines and Sex and Gender in Research
Cell line source(s)	
Authentication	
Mycoplasma contaminati	on
Commonly misidentified (See ICLAC register)	ines
Palaeontology and	d Archaeology
Specimen provenance	
Specimen deposition	
Dating methods	
Tick this box to confirm	n that the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	
Note that full information on tl	ne approval of the study protocol must also be provided in the manuscript.
	r research organisms udies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in
Laboratory animals	Provided
Wild animals	n/a
Reporting on sex	n/a
Field-collected samples	n/a
Ethics oversight	Provided
Note that full information on tl	ne approval of the study protocol must also be provided in the manuscript.
Clinical data	
Policy information about <u>cli</u> All manuscripts should comply	nical studies with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	n/a
Study protocol	n/a
Data collection	n/a
Outcomes	n/a

Dual use research of concern

Policy information about <u>dual use research of concern</u>

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No Yes	
x Public health	
X National security	
Crops and/or livest	ock
Ecosystems	
Any other significar	nt area
Experiments of concer	n
Does the work involve any	of these experiments of concern:
No Yes	
x Demonstrate how t	o render a vaccine ineffective
X Confer resistance to	o therapeutically useful antibiotics or antiviral agents
Enhance the viruler	nce of a pathogen or render a nonpathogen virulent
x Increase transmissi	bility of a pathogen
X Alter the host range	e of a pathogen
x Enable evasion of d	iagnostic/detection modalities
X Enable the weapon	ization of a biological agent or toxin
X Any other potential	ly harmful combination of experiments and agents
Plants	
Seed stocks	n/a
Novel plant genotypes	n/a
Authentication	
Authentication	n/a
ChIP-seq	
Data deposition	
Confirm that both raw	and final processed data have been deposited in a public database such as GEO.
Confirm that you have	deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links	
May remain private before public	ation. n/a
Files in database submissi	on n/a
Genome browser session	
(e.g. <u>UCSC</u>)	n/a
Methodology	
Replicates	n/a
Sequencing depth	
	n/a
Antibodies	n/a
Peak calling parameters	n/a
Data quality	n/a

Software

Flow Cytometry	
Plots Confirm that:	
	er and fluorochrome used (e.g. CD4-FITC).
	ble. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with	
	of cells or percentage (with statistics) is provided.
Methodology	
Sample preparation	provided
Instrument	provided
Software	
	provided
Cell population abundance	provided
Gating strategy	provided
X Tick this box to confirm that a	figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance im	naging
Experimental design	
Design type	n/a
Design specifications	
	n/a
Behavioral performance measure	s n/a
Imaging type(s)	n/a
Field strength	n/a
Sequence & imaging parameters	n/a
Area of acquisition	n/a
Diffusion MRI Used	X Not used
Preprocessing	
Preprocessing software	n/a
Normalization	n/a
Normalization template	n/a
Noise and artifact removal	n/a
Volume censoring	n/a
Statistical modeling & inferer	nce
Model type and settings	n/a
-cc	

Model type and settings	n/a
Effect(s) tested	n/a
Specify type of analysis: W	hole brain ROI-based Both

nature
oortfo
olio reporting sumr
summa

ŧ	
đ	
Ņ	
u	w

Statistic type for inference	
(See Eklund et al. 2016)	
Correction	
Models & analysis	
n/a Involved in the study	
x Functional and/or effective connectivity	
x Graph analysis	
$oxed{x}$ Multivariate modeling or predictive analy	sis
Functional and/or effective connectivity	
Graph analysis	

Multivariate modeling and predictive analysis